The data from TROPiCS-02 have resulted in the inclusion of SG as a category I option in the 2023 NCCN Guidelines for Breast Cancer and its recommendation as a second-line treatment for HR+/HER2− breast cancer patients who have previously received endocrine therapy (ET) and CDK4/6 inhibitors [21]. This evidence concerns the gene CDK4 and breast carcinoma.